Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 76 Carcinoma, Hepatocellular 47 Ovarian Neoplasms 40 Carcinoma, Non-Small-Cell Lung 26 Neoplasms 22 Fallopian Tube Neoplasms 17 Lung Neoplasms 15 Neoplasm Metastasis 13 Breast Neoplasms 13 Glioblastoma 12 Endometrial Neoplasms 12 Brain Neoplasms 12 Colonic Neoplasms 11 Triple Negative Breast Neoplasms 10 Rectal Neoplasms 10 Uterine Cervical Neoplasms 9 Liver Neoplasms 9 Stomach Neoplasms 8 Colorectal Cancer Metastatic 7 Pancreatic Neoplasms 6 Advanced Solid Tumors 6 Recurrence 5 Melanoma 5 Glioma 5 Carcinoma, Renal Cell 5 Carcinoma, Ovarian Epithelial 5 Biliary Tract Neoplasms 5 Solid Tumor 4 Meningeal Carcinomatosis 4 Gastrointestinal Neoplasms 4

Interventions

liposomal doxorubicin 3 1-dodecylpyridoxal 2 pembrolizumab 1 mirabegron 1 disitamab vedotin 1 anlotinib 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ovarian Cancer Recurrent × Bevacizumab × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡